Story perspectives

Novo Nordisk Partners with OpenAI to Enhance Drug Discovery

4/14/2026

Summary

Story summary

Danish pharmaceutical company Novo Nordisk has partnered with OpenAI to integrate artificial intelligence across drug discovery, manufacturing, and commercial activities.
The collaboration aims to boost efficiency and competitiveness in obesity drug markets, where Novo Nordisk competes with Eli Lilly.
Mike Doustdar said the initiative will 'supercharge' scientists, not replace them, with pilots starting immediately and full integration by 2026.
The agreement includes strict data governance and employee AI training.

History

Historical Context

In 1989, Novo Nordisk was formed through the merger of two Danish insulin companies, establishing itself as a leader in diabetes and obesity medications. The 2010 launch of Saxenda marked a significant milestone, generating over $1 billion in sales. In 2023, Novo Nordisk partnered with OpenAI to leverage artificial intelligence in drug discovery, aiming to enhance innovation in the competitive obesity market.

1 of 2

Story summary

Danish pharmaceutical company Novo Nordisk has partnered with OpenAI to integrate artificial intelligence across drug discovery, manufacturing, and commercial activities.
The collaboration aims to boost efficiency and competitiveness in obesity drug markets, where Novo Nordisk competes with Eli Lilly.
Mike Doustdar said the initiative will 'supercharge' scientists, not replace them, with pilots starting immediately and full integration by 2026.
The agreement includes strict data governance and employee AI training.

1 / 2